Works matching DE "GEFITINIB"

Results: 819

Cost-effectiveness analysis of the first-line EGFR-TKIs in patients with non-small cell lung cancer harbouring EGFR mutations.

Published in:

2020

By:

Holleman, Marscha S.;
Al, Maiwenn J.;
Zaim, Remziye;
Groen, Harry J. M.;
Uyl-de Groot, Carin A.

Publication type:

journal article

Cost-effectiveness analysis of EGFR mutation testing in patients with non-small cell lung cancer (NSCLC) with gefitinib or carboplatin-paclitaxel.

Published in:

2016

By:

Arrieta, Oscar;
Anaya, Pablo;
Morales-Oyarvide, Vicente;
Ramírez-Tirado, Laura;
Polanco, Ana;
Ramírez-Tirado, Laura Alejandra;
Polanco, Ana C

Publication type:

journal article

Impact of histamine type-2 receptor antagonists on the anticancer efficacy of gefitinib in patients with non-small cell lung cancer.

Published in:

European Journal of Clinical Pharmacology, 2021, v. 77, n. 3, p. 381, doi. 10.1007/s00228-020-03013-9

By:

Saito, Yoshitaka;
Takekuma, Yoh;
Kobayashi, Masaki;
Shinagawa, Naofumi;
Shimizu, Yasushi;
Kinoshita, Ichiro;
Dosaka-Akita, Hirotoshi;
Iseki, Ken;
Sugawara, Mitsuru

Publication type:

Article

Safety and CSF distribution of high-dose erlotinib and gefitinib in patients of non–small cell lung cancer (NSCLC) with brain metastases.

Published in:

European Journal of Clinical Pharmacology, 2020, v. 76, n. 10, p. 1427, doi. 10.1007/s00228-020-02926-9

By:

Shriyan, Bharati;
Patil, Deepali;
Gurjar, Murari;
Nookala, Manjunath;
Patil, Anand;
Kannan, Sadhana;
Patil, Vijay;
Joshi, Amit;
Noronha, Vanita;
Prabhash, Kumar;
Gota, Vikram

Publication type:

Article

Erlotinib or Gefitinib for Treating Advanced Epidermal Growth Factor Receptor Mutation–Positive Lung Cancer in Aotearoa New Zealand: Protocol for a National Whole-of-Patient-Population Retrospective Cohort Study and Results of a Validation Substudy.

Published in:

JMIR Research Protocols, 2024, v. 13, p. 1, doi. 10.2196/51381

By:

Aye, Phyu Sin;
Barnes, Joanne;
Laking, George;
Cameron, Laird;
Anderson, Malcolm;
Luey, Brendan;
Delany, Stephen;
Harris, Dean;
McLaren, Blair;
Brenman, Elliott;
Wong, Jayden;
Lawrenson, Ross;
Arendse, Michael;
Tin Tin, Sandar;
Elwood, Mark;
Hope, Philip;
McKeage, Mark James

Publication type:

Article

Development of asolectin-based liposomal formulation for controlled and targeted delivery of erlotinib as a model drug for EGFR monotherapy.

Published in:

Journal of Liposome Research, 2022, v. 32, n. 4, p. 386, doi. 10.1080/08982104.2022.2040532

By:

Pardeshi, Snehal;
Tiwari, Amrendra;
Titame, Uday;
Singh, Pankaj K;
Yadav, Pavan Kumar;
Chourasia, Manish K.

Publication type:

Article

Lipidomics reveals that sustained SREBP-1-dependent lipogenesis is a key mediator of gefitinib-acquired resistance in EGFR-mutant lung cancer.

Published in:

Cell Death Discovery, 2021, v. 7, n. 1, p. 1, doi. 10.1038/s41420-021-00744-1

By:

Xu, Chuncao;
Zhang, Lei;
Wang, Daifei;
Jiang, Shiqin;
Cao, Di;
Zhao, Zhongxiang;
Huang, Min;
Jin, Jing

Publication type:

Article

Synergistic Action of Gefitinib and GSK41364A Simultaneously Loaded in Ratiometrically-Engineered Polymeric Nanoparticles for Glioblastoma Multiforme.

Published in:

Journal of Clinical Medicine, 2019, p. 367, doi. 10.3390/jcm8030367

By:

Velpurisiva, Praveena;
Rai, Prakash

Publication type:

Article

Preparation and evaluation of biological activity of ZSM-5 nanoparticles loaded with gefitinib for the treatment of non-small cell lung carcinoma.

Published in:

Pharmacia (0428-0296), 2024, v. 71, n. 1, p. 1, doi. 10.3897/pharmacia.71.e112449

By:

Al-Sahlawi, Farah;
Al-Ani, Israa;
El-Tanani, Mohamed;
Farooq, Hafiz Aadil

Publication type:

Article

Evaluation of Anticancer Activity of 76 Plant Species Collected in Andalusia (Spain) against Lung Cancer Cells.

Published in:

Plants (2223-7747), 2023, v. 12, n. 18, p. 3275, doi. 10.3390/plants12183275

By:

Jiménez-González, Víctor;
Benítez, Guillermo;
Pastor, Julio Enrique;
López-Lázaro, Miguel;
Calderón-Montaño, José Manuel

Publication type:

Article

Lentivirus-mediated silencing of CNTN1 enhances gefitinib sensitivity by reversing epithelial-mesenchymal transition in lung adenocarcinoma A549 cells.

Published in:

Oncology Letters, 2021, v. 21, n. 6, p. N.PAG, doi. 10.3892/ol.2021.12694

By:

Hu, Chun-Sheng;
Huang, Jiu-Hong;
Yang, Dong-Lin;
Xu, Chuan;
Xu, Zhi-Gang;
Tan, Hong-Bo;
Chen, Zhong-Zhu

Publication type:

Article

Overexpression of CTEN is associated with gefitinib resistance in non-small cell lung cancer.

Published in:

Oncology Letters, 2021, v. 21, n. 1, p. N.PAG

By:

Lu, Xiangdong;
Zhang, Yao;
Pan, Yukai;
Cao, Minmin;
Zhou, Xie;
Zhang, Tingrong

Publication type:

Article

Gefitinib induces non‑small cell lung cancer H1650 cell apoptosis through downregulating tumor necrosis factor‑related apoptosis‑inducing ligand expression levels.

Published in:

Oncology Letters, 2018, v. 16, n. 4, p. 4768, doi. 10.3892/ol.2018.9162

By:

Yi, Hanjie;
Li, Shanfeng;
Li, Hui;
Wang, Peng;
Zheng, Hongyu;
Cheng, Xiaochun

Publication type:

Article

Overexpression of Napsin A resensitizes drug-resistant lung cancer A549 cells to gefitinib by inhibiting EMT.

Published in:

Oncology Letters, 2018, v. 16, n. 2, p. 2533, doi. 10.3892/ol.2018.8963

By:

Zhou, Linshui;
Lv, Xin;
Yang, Junchao;
Zhu, Yuanhong;
Wang, ZhEN;
Xu, TingzhEN

Publication type:

Article

Methodological comparison of the allele refractory mutation system and direct sequencing for detecting EGFR mutations in NSCLC, and the association of EGFR mutations with patient characteristics.

Published in:

Oncology Letters, 2018, v. 16, n. 1, p. 1087, doi. 10.3892/ol.2018.8775

By:

Wu, Minmin;
Pan, Xiaodong;
Xu, Yaya;
Wu, Siying;
Wu, Xiuling;
Chen, Bicheng

Publication type:

Article

Exosome‑mediated gefitinib resistance in lung cancer HCC827 cells via delivery of miR‑21.

Published in:

Oncology Letters, 2018, v. 15, n. 6, p. 9811, doi. 10.3892/ol.2018.8604

By:

Jing, ChangwEN;
Cao, Haixia;
Qin, Xiaobing;
Yu, Shaorong;
Wu, Jianzhong;
Wang, Zhuo;
Ma, Rong;
FENg, JifENg

Publication type:

Article

LXR ligands induce apoptosis of EGFR-TKI-resistant human lung cancer cells in vitro by inhibiting Akt-NF-κB activation.

Published in:

Oncology Letters, 2018, v. 15, n. 5, p. 7168, doi. 10.3892/ol.2018.8182

By:

Liu, Siwen;
Cao, Haixia;
Chen, Dan;
Yu, Shaorong;
Sha, Huanhuan;
Wu, Jianzhong;
Ma, Rong;
Wang, Zhuo;
Jing, Changwen;
Zhang, Junying;
Feng, Jifeng

Publication type:

Article

Lentivirus‑mediated silencing of HOTAIR lncRNA restores gefitinib sensitivity by activating Bax/Caspase‑3 and suppressing TGF‑α/EGFR signaling in lung adenocarcinoma.

Published in:

Oncology Letters, 2018, v. 15, n. 3, p. 2829, doi. 10.3892/ol.2017.7656

By:

Liu, Yuanshun;
Jiang, Hua;
Zhou, Hongbin;
Ying, Xiwang;
Wang, Zhehua;
Yang, Yang;
Xu, Wulin;
He, Xujun;
Li, Yaqing

Publication type:

Article

Epidermal growth factor receptor somatic mutation analysis in 354 Chinese patients with non-small cell lung cancer.

Published in:

Oncology Letters, 2018, v. 15, n. 2, p. 2131, doi. 10.3892/ol.2017.7622

By:

Quan, Xueping;
Gao, Hongjun;
Wang, Zhikuan;
Li, Jie;
Zhao, Wentao;
Liang, Wei;
Yu, Qiang;
Guo, Dongliang;
Hao, Zhanping;
Liu, Jingxin

Publication type:

Article

MicroRNA-1 inhibits tumorigenicity of esophageal squamous cell carcinoma and enhances sensitivity to gefitinib.

Published in:

Oncology Letters, 2018, v. 15, n. 1, p. 963, doi. 10.3892/ol.2017.7378

By:

Yu, Qianqian;
Liu, Yiqian;
Wen, Chengcai;
Zhao, Yongzhao;
Jin, Shidai;
Hu, Youfang;
Wang, Feng;
Chen, Liang;
Zhang, Bin;
Wang, Wei;
Zhu, Quan;
Guo, Renhua

Publication type:

Article

Sulforaphane reverses gefitinib tolerance in human lung cancer cells via modulation of sonic hedgehog signaling.

Published in:

Oncology Letters, 2018, v. 15, n. 1, p. 109, doi. 10.3892/ol.2017.7293

By:

Wang, Fanping;
Wang, Wenjun;
Li, Junpeng;
Zhang, Jingjing;
Wang, Xia;
Wang, Mingyong

Publication type:

Article

Interleukin-6 identified as an important factor in hypoxia- and aldehyde dehydrogenase-based gefitinib adaptive resistance in non-small cell lung cancer cells.

Published in:

Oncology Letters, 2017, v. 14, n. 3, p. 3445, doi. 10.3892/ol.2017.6613

By:

Shi-Min An;
Hui-Min Lei;
Xu-Ping Ding;
Fan Sun;
Chun Zhang;
Ya-Bin Tang;
Hong-Zhuan Chen;
Ying Shen;
Liang Zhu

Publication type:

Article

Evaluation of erlotinib for the treatment of patients with non-small cell lung cancer with epidermal growth factor receptor wild type.

Published in:

Oncology Letters, 2017, v. 14, n. 1, p. 306, doi. 10.3892/ol.2017.6118

By:

FUMIHIKO HIRAI;
MAKOTO EDAGAWA;
SHINICHIRO SHIMAMATSU;
RYO TOYOZAWA;
GOUJI TOYOKAWA;
KANAME NOSAKI;
MASAFUMI YAMAGUCHI;
TAKASHI SETO;
MITSUHIRO TAKENOYAMA;
YUKITO ICHINOSE

Publication type:

Article

Comparison of the effectiveness of erlotinib, gefitinib, and afatinib for treatment of non-small cell lung cancer in patients with common and rare EGFR gene mutations.

Published in:

Oncology Letters, 2017, v. 13, n. 6, p. 4433, doi. 10.3892/ol.2017.5980

By:

KRAWCZYK, PAWEL;
KOWALSKI, DARIUSZ M.;
RAMLAU, RODRYG;
KALINKA-WARZOCHA, EWA;
WINIARCZYK, KINGA;
STENCEL, KATARZYNA;
POWRÓZEK, TOMASZ;
RESZKA, KATARZYNA;
WOJAS-KRAWCZYK, KAMILA;
BRYL, MACIEJ;
WÓJCIK-SUPERCZYŃSKA, MAGDALENA;
GŁOGOWSKI, MACIEJ;
BARINOW-WOJEWÓDZKI, ALEKSANDER;
MILANOWSKI, JANUSZ;
KRZAKOWSKI, MACIEJ

Publication type:

Article

Increased MIR31HG lncRNA expression increases gefitinib resistance in non-small cell lung cancer cell lines through the EGFR/PI3K/AKT signaling pathway.

Published in:

Oncology Letters, 2017, v. 13, n. 5, p. 3494, doi. 10.3892/ol.2017.5878

By:

BING WANG;
HONG JIANG;
LIMIN WANG;
XUEQIN CHEN;
KAN WU;
SHIRONG ZHANG;
SHENGLIN MA;
BING XIA

Publication type:

Article

HER2 overexpression reverses the relative resistance of EGFR-mutant H1975 cell line to gefitinib.

Published in:

Oncology Letters, 2016, v. 12, n. 6, p. 5363, doi. 10.3892/ol.2016.5373

By:

JING XU;
LI SHEN;
BI-CHENG ZHANG;
WEN-HONG XU;
SHU-QIN RUAN;
CHI PAN;
QI-CHUN WEI

Publication type:

Article

Detection of microRNA-200b may predict the inhibitory effect of gefitinib on non-small cell lung cancer and its potential mechanism.

Published in:

Oncology Letters, 2016, v. 12, n. 6, p. 5349, doi. 10.3892/ol.2016.5365

By:

ZHIWU LIU;
LIQIONG YAO;
BANGYUN TAN;
LI LI;
BAOJIN CHEN

Publication type:

Article

Relationship between miR-7 expression and treatment outcomes with gefitinib in non-small cell lung cancer.

Published in:

Oncology Letters, 2016, v. 12, n. 6, p. 4613, doi. 10.3892/ol.2016.5290

By:

KUN MOU;
WEIWEI GU;
CUIHUA GU;
JINZHONG ZHANG;
WENJIE QWANG;
GANG REN;
JING TIAN

Publication type:

Article

Gefitinib induces lung cancer cell autophagy and apoptosis via blockade of the PI3K/AKT/mTOR pathway.

Published in:

Oncology Letters, 2016, v. 12, n. 1, p. 63, doi. 10.3892/ol.2016.4606

By:

ZHONG-QUAN ZHAO;
ZHONG-YANG YU;
JIE LI;
XUE-NONG OUYANG

Publication type:

Article

Gefitinib as first line therapy in Malaysian patients with EGFR mutation-positive non-small-cell lung cancer: A single-center retrospective study.

Published in:

Oncology Letters, 2016, v. 11, n. 4, p. 2757, doi. 10.3892/ol.2016.4322

By:

ABDULLAH, MATIN MELLOR;
BHAT, AMIT;
MOHAMED, AHMAD KAMAL;
CHING, FOO YOKE;
AHMED, NIDA;
GANTOTTI, SANDEEP

Publication type:

Article

Integrin β1-mediated acquired gefitinib resistance in non-small cell lung cancer cells occurs via the phosphoinositide 3-kinase-dependent pathway.

Published in:

Oncology Letters, 2016, v. 11, n. 1, p. 535, doi. 10.3892/ol.2015.3945

By:

QIN-FANG DENG;
BO SU;
YIN-MIN ZHAO;
LIANG TANG;
JIE ZHANG;
CAI-CUN ZHOU

Publication type:

Article

Epidermal growth factor receptor exon 20 p.S768I mutation in non-small cell lung carcinoma: A case report combined with a review of the literature and investigation of clinical significance.

Published in:

2016

By:

IMPROTA, GIUSEPPINA;
PETTINATO, ANGELA;
GIERI, STEFANIA;
SCANDURRA, GIUSEPPA;
SKOVRIDER-RUMINSKI, WOJCIECH;
HØGDALL, ESTRID;
FRAGGETTA, FILIPPO

Publication type:

Case Study

Synergistic interaction between MEK inhibitor and gefitinib in EGFR-TKI-resistant human lung cancer cells.

Published in:

Oncology Letters, 2015, v. 10, n. 4, p. 2652, doi. 10.3892/ol.2015.3577

By:

SUXIA LI;
SUXIU CHEN;
YIYAN JIANG;
JIEFAN LIU;
XIAOLEI YANG;
SHICHAO QUAN

Publication type:

Article

Combined therapy with EGFR TKI and gambogic acid for overcoming resistance in EGFR-T790M mutant lung cancer.

Published in:

Oncology Letters, 2015, v. 10, n. 4, p. 2063, doi. 10.3892/ol.2015.3599

By:

CHENGDE WANG;
WEI WANG;
CHAOYANG WANG;
YIJUN TANG;
HUI TIAN

Publication type:

Article

L858R-positive lung adenocarcinoma with KRAS G12V, EGFR T790M and EGFR L858R mutations: A case report.

Published in:

Oncology Letters, 2015, v. 10, n. 3, p. 1293, doi. 10.3892/ol.2015.3435

By:

XIANHONG XIANG;
JIANXING YU;
YINGRONG LAI;
WEILING HE;
SHUHUA LI;
LIANTANG WANG;
ZUNFU KE

Publication type:

Article

Gefitinib-induced intestinal obstruction in advanced non-small cell lung carcinoma: A case report.

Published in:

Oncology Letters, 2015, v. 10, n. 3, p. 1277, doi. 10.3892/ol.2015.3463

By:

YI-CHEN LIANG;
GANGWU;
JING CHENG;
DAN-DAN YU;
HONG-GE WU

Publication type:

Article

Re-administration of gefitinib following diffuse interstitial lung disease in a patient with advanced lung adenocarcinoma: A case report and review of the literature.

Published in:

2015

By:

XUELI ZHANG;
HUIQIAO LI;
MIN ZHU;
YUHUI ZHANG

Publication type:

Case Study

Clinical significance of gefitinib antitumor activity in patients with lung adenocarcinoma.

Published in:

Oncology Letters, 2015, v. 9, n. 1, p. 257, doi. 10.3892/ol.2014.2664

By:

ZHUN WANG;
QIAN-BO HAN;
JIA-LEI GU;
XIN-MIN YU;
XIAO-JIANG SUN;
QING-REN LIN;
JUN FANG;
YUE-ZHEN WANG;
YA-PING XU;
WEI-MIN MAO

Publication type:

Article

A new receptor tyrosine kinase inhibitor, icotinib, for patients with lung adenocarcinoma cancer without indication for chemotherapy.

Published in:

Oncology Letters, 2014, v. 8, n. 4, p. 1563, doi. 10.3892/ol.2014.2386

By:

XIAO ZHENG;
GUAN LIU;
SHENGYE WANG;
YUNLI ZHANG;
WENLONG BAO;
DEHOU DENG;
WEIMING MAO;
MEIYU FANG

Publication type:

Article

High efficacy of gefitinib in the treatment of EGFR mutation-positive advanced non-small cell lung adenocarcinoma: A case report.

Published in:

2014

By:

ZHONGCHAO WANG;
JIANJUN CHU

Publication type:

Case Study

Lung adenocarcinoma harboring L858R and T790M mutations in epidermal growth factor receptor, with poor response to gefitinib: A case report.

Published in:

2014

By:

YUE FENG WANG;
XIANHONG XIANG;
XIAOJUAN PEI;
SHUHUA LI;
CUILAN TANG;
LIANTANG WANG;
ZUN-FU KE

Publication type:

Case Study

Effect of Paris saponin I on radiosensitivity in a gefitinib-resistant lung adenocarcinoma cell line.

Published in:

Oncology Letters, 2014, v. 7, n. 6, p. 2065, doi. 10.3892/ol.2014.2020

By:

HAO JIANG;
PENGJUN ZHAO;
JIANGUO FENG;
DAN SU;
SHENGLIN MA

Publication type:

Article

Rechallenge with gefitinib following severe drug-induced hepatotoxicity in a patient with advanced non-small cell lung cancer: A case report and literature review.

Published in:

2014

By:

XUEQIN CHEN;
YUELONG PAN;
SHIRONG ZHANG;
DADONG CHEN;
SHAOYU YANG;
XIN LI;
SHENGLIN MA

Publication type:

Case Study

Treatment response to osimertinib in a patient with leptomeningeal metastasis from lung adenocarcinoma following failure of gefitinib and erlotinib: A case report.

Published in:

2018

By:

Li, Junjun;
Liu, Xiaomei;
Yuan, Caijun

Publication type:

Abstract

Randomized phase II study of sequential carboplatin plus paclitaxel and gefitinib in chemotherapy-naïve patients with advanced or metastatic non-small-cell lung cancer: Long-term follow-up results.

Published in:

Molecular & Clinical Oncology, 2017, v. 6, n. 1, p. 56, doi. 10.3892/mco.2016.1076

By:

EMI KUBO;
NOBORU YAMAMOTO;
HIROSHI NOKIHARA;
YUTAKA FUJIWARA;
HIDEHITO HORINOUCHI;
SHINTARO KANDA;
YASUSHI GOTO;
YUICHIRO OHE

Publication type:

Article

Successful treatment of non‑small‑cell lung cancer with afatinib and a glucocorticoid following gefitinib‑ and erlotinib‑induced interstitial lung disease: A case report.

Published in:

Molecular & Clinical Oncology, 2016, v. 5, n. 4, p. 488, doi. 10.3892/mco.2016.981

By:

TETSUO TANI;
KATSUHIKO NAOKI;
TAKANORI ASAKURA;
TOSHIYUKI HIRANO;
SHOJI SUZUKI;
KEITA MASUZAWA;
HANAKO HASEGAWA;
AOI KURODA;
HIROYUKI YASUDA;
MAKOTO ISHII;
KENZO SOEJIMA;
TOMOKO BETSUYAKU

Publication type:

Article

EGFR and K-RAS mutations and ERCC1, TUBB3, TYMS, RRM1 and EGFR mRNA expression in non-small cell lung cancer: Correlation with clinical response to gefitinib or chemotherapy.

Published in:

Molecular & Clinical Oncology, 2015, v. 3, n. 5, p. 1123, doi. 10.3892/mco.2015.611

By:

NANNAN GUO;
WEN ZHANG;
BAOSHI ZHANG;
YINGJIE LI;
JIAN TANG;
SHAOJUN LI;
YINGNAN ZHAO;
YUNLONG ZHAO;
HUI XIA;
CHANGHAI YU

Publication type:

Article

Plasma neuron-specific enolase level as a prognostic marker in patients with non-small cell lung cancer receiving gefitinib.

Published in:

Molecular & Clinical Oncology, 2015, v. 3, n. 4, p. 62, doi. 10.3892/mco.2015.568

By:

MINEHIKO INOMATA;
RYUJI HAYASHI;
AZUSA YAMAMOTO;
KOTARO TOKUI;
CHIHIRO TAKA;
SEISUKE OKAZAWA;
KENTA KAMBARA;
KENSUKE SUZUKI;
TOMOMI ICHIKAWA;
TORU YAMADA;
TOSHIRO MIWA;
TATSUHIKO KASHII;
SHOKO MATSUI;
KAZUYUKI TOBE;
JOHJI IMURA

Publication type:

Article

Advantages of CyberKnife for inoperable stage I peripheral non-small-cell lung cancer compared to three-dimensional conformal radiotherapy.

Published in:

Molecular & Clinical Oncology, 2015, v. 3, n. 2, p. 442, doi. 10.3892/mco.2014.475

By:

AN-NA TONG;
PENG YAN;
GUANG-HUI YUAN;
XIAO-YAN LV;
HAI GONG;
HUI ZHAO;
YAN-MING WANG

Publication type:

Article

Epidermal growth factor receptor-tyrosine kinase inhibitors for non-small-cell lung cancer patients aged 80 years or older: A retrospective analysis.

Published in:

Molecular & Clinical Oncology, 2015, v. 3, n. 2, p. 403, doi. 10.3892/mco.2014.453

By:

MAKOTO NAKAO;
HIDEKI MURAMATSU;
KAZUKI SONE;
SACHIKO AOKI;
HARATA AKIKO;
YUSUKE KAGAWA;
HIDEFUMI SATO;
TAKEFUMI KUNIEDA

Publication type:

Article